| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Florin Graur | Q80102570 |
| Cornelia Braicu | Q85780737 | ||
| Ioana Berindan-Neagoe | Q87613611 | ||
| Ovidiu Balacescu | Q89209290 | ||
| Claudia Burz | Q90698536 | ||
| Alexandru Irimie | Q92061610 | ||
| Victor Cristea | Q108750578 | ||
| P2860 | cites work | Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein | Q24322844 |
| Characterization of insulin-like-growth factor II (IGF II) mRNA positive hepatic altered foci and IGF II expression in hepatocellular carcinoma during diethylnitrosamine-induced hepatocarcinogenesis in rats | Q24811580 | ||
| Serum levels of IL-10, IL-15 and soluble tumour necrosis factor-alpha (TNF-alpha) receptors in type C chronic liver disease | Q27480413 | ||
| Hepatitis C Virus Induces E6AP-Dependent Degradation of the Retinoblastoma Protein | Q27485880 | ||
| Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production | Q29614596 | ||
| Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. | Q30332934 | ||
| Diagnosis of hepatocellular carcinoma. | Q30490554 | ||
| Candidate markers for the detection of hepatocellular carcinoma in low-molecular weight fraction of serum | Q33295308 | ||
| Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study | Q33385313 | ||
| Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. | Q33831996 | ||
| Serum tumor markers for detection of hepatocellular carcinoma | Q34501851 | ||
| Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer | Q34560933 | ||
| The prognostic molecular markers in hepatocellular carcinoma | Q34668320 | ||
| Cytokine profile in Egyptian hepatitis C virus genotype-4 in relation to liver disease progression | Q35165855 | ||
| Angiopoietin switching regulates angiogenesis and progression of human hepatocellular carcinoma | Q35587117 | ||
| Newer markers for hepatocellular carcinoma | Q35929142 | ||
| Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma | Q35945177 | ||
| Effect of bax, bcl-2 and bcl-xL on regulating apoptosis in tissues of normal liver and hepatocellular carcinoma | Q36308391 | ||
| The role of cytokines in hepatocellular carcinoma | Q36583165 | ||
| Increased plasma apoM levels in the patients suffered from hepatocellular carcinoma and other chronic liver diseases | Q36823348 | ||
| Changing pattern of hepatocellular carcinoma (HCC) and its risk factors in Egypt: possibilities for prevention | Q37112289 | ||
| DNA methylation in hepatocellular carcinoma | Q37113559 | ||
| Hepatocellular carcinoma: latest developments | Q37137357 | ||
| Hepatocellular cancer arises from loss of transforming growth factor beta signaling adaptor protein embryonic liver fodrin through abnormal angiogenesis | Q37355553 | ||
| Early development of sunitinib in hepatocellular carcinoma | Q37357314 | ||
| Liver stem cells and hepatocellular carcinoma | Q37358938 | ||
| HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver | Q38494681 | ||
| P53 mutations in hepatocellular carcinoma patients in Egypt. | Q38988114 | ||
| Evaluation of serum squamous cell carcinoma antigen as a novel biomarker for diagnosis of hepatocellular carcinoma in Egyptian patients | Q39089577 | ||
| MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells | Q39913331 | ||
| p27Kip1 promotes migration of metastatic hepatocellular carcinoma cells | Q39941728 | ||
| Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas | Q39960626 | ||
| cFLIPL prevents TRAIL-induced apoptosis of hepatocellular carcinoma cells by inhibiting the lysosomal pathway of apoptosis | Q40175794 | ||
| EGFR is phosphorylated at Ty845 in hepatocellular carcinoma | Q40238980 | ||
| EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer | Q40361923 | ||
| Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets | Q40494233 | ||
| Cyclooxygenases in hepatocellular carcinoma. | Q42726279 | ||
| Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor | Q42833272 | ||
| Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases. | Q43031477 | ||
| Genetic alterations and oncogenic pathways in hepatocellular carcinoma. | Q44049176 | ||
| Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. | Q44124129 | ||
| Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma | Q44696802 | ||
| Angiogenesis soluble factors as hepatocellular carcinoma noninvasive markers for monitoring hepatitis C virus cirrhotic patients awaiting liver transplantation. | Q44934094 | ||
| Quantitative proteomic signature of liver cancer cells: tissue transglutaminase 2 could be a novel protein candidate of human hepatocellular carcinoma | Q45170580 | ||
| Molecular mechanism of p73-mediated regulation of hepatitis B virus core promoter/enhancer II: implications for hepatocarcinogenesis | Q45396493 | ||
| Differential DNA methylation associated with hepatitis B virus infection in hepatocellular carcinoma | Q45403494 | ||
| Activation of Akt-mTOR-p70S6K pathway in angiogenesis in hepatocellular carcinoma. | Q46349987 | ||
| Abnormal expression of insulin-like growth factor-II and its dynamic quantitative analysis at different stages of hepatocellular carcinoma development | Q46435942 | ||
| Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential | Q46856581 | ||
| Hepatocellular carcinoma and sex. | Q46909917 | ||
| pRb2/p130, vascular endothelial growth factor, p27(KIP1), and proliferating cell nuclear antigen expression in hepatocellular carcinoma: their clinical significance | Q47433429 | ||
| Serum insulin-like growth factor-II and alpha-fetoprotein as tumor markers of hepatocellular carcinoma | Q47990710 | ||
| Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter. | Q53317472 | ||
| Relationship between p53 overexpression and the proliferative activity in hepatocellular carcinoma. | Q53407989 | ||
| Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma. | Q53510185 | ||
| Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma. | Q53657108 | ||
| Expression of matrix metalloproteinases (MMPs) in cultured hepatocellular carcinoma (HCC) cells and surgically resected HCC tissues. | Q54665206 | ||
| Association between serum hepatocyte growth factor and survival in untreated hepatocellular carcinoma | Q57003108 | ||
| SCCA antigen combined with alpha-fetoprotein as serologic markers of HCC | Q61617949 | ||
| Hepatocellular carcinoma cell cycle: study of Long-Evans cinnamon rats. | Q64905197 | ||
| Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis | Q70646154 | ||
| Abnormal expression of hepatoma specific gamma-glutamyl transferase and alteration of gamma-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma | Q73459294 | ||
| Autocrine stimulatory mechanism by transforming growth factor beta in human hepatocellular carcinoma | Q73574342 | ||
| P53 tumor suppressor gene mutations in hepatocellular carcinoma patients in India | Q73595105 | ||
| Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features | Q74669751 | ||
| Hepatocellular carcinoma | Q77755269 | ||
| [Expression and significance of EGF mRNA and EGFR mRNA in hepatocellular carcinoma] | Q80331695 | ||
| Hepatocellular carcinoma: an update | Q80553066 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q82816450 | ||
| Glypican-3 as a serum marker for hepatocellular carcinoma | Q95818699 | ||
| P433 | issue | 4 | |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P304 | page(s) | 191-199 | |
| P577 | publication date | 2009-07-20 | |
| P1433 | published in | Gastroenterology research | Q27723942 |
| P1476 | title | Hepatocellular Carcinoma: Tumorigenesis and Prediction Markers | |
| P478 | volume | 2 |
| Q37728367 | Cholera toxin inhibits human hepatocarcinoma cell proliferation in vitro via suppressing ATX/LPA axis |
| Q42279286 | Epidermal growth factor, its receptor and transforming growth factor-β1 in the diagnosis of HCV-induced hepatocellular carcinoma. |
| Q90020170 | Evaluation of Ferritin and Transferrin Ratio as a Prognostic Marker for Hepatocellular Carcinoma |
| Q37031754 | Hepatocellular carcinoma ablation and possible immunity in the age of nanosecond pulsed electric fields |
| Q35513609 | Inhibition of diethylnitrosamine-initiated alcohol-promoted hepatic inflammation and precancerous lesions by flavonoid luteolin is associated with increased sirtuin 1 activity in mice |
| Q91797808 | Tumorigenesis, diagnosis, and therapeutic potential of exosomes in liver cancer |
Search more.